Research
Hormonal
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) help manage type 2 diabetes mellitus (T2DM) by controlling blood sugar and promoting weight loss.
GLP-1RAs can be considered as a treatment option for patients with T2DM who need to manage blood sugar and weight.
StrongSupportsmedium confidence
GLP-1RAs were initially introduced as a rising star for managing T2DM, with patients benefiting from the control of blood sugar and weight loss.
Why this rating
The abstract discusses the established role of GLP-1RAs in clinical practice.
Source
Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse effects, and future directions
Alaa Ismail et al. · World Journal of Gastrointestinal Pharmacology and Therapeutics · 2025
DOI 10.4292/wjgpt.v16.i3.107148
reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →